14887-4 |
Primidone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Primidone [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14887-4 |
|
|
|
|
Both |
|
|
|
0 |
Primidone SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mysoline; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14888-2 |
Procainamide |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Procainamide [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14888-2 |
|
|
|
|
Both |
|
|
|
0 |
Procainamide SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; PA; Pl; Plasma; Plsm; Point in time; Procan; Pronestyl; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14889-0 |
Procainamide+N-acetylprocainamide |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Procainamide+N-acetylprocainamide [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14889-0 |
|
|
|
|
Both |
|
|
|
0 |
Procainamide+NAPA SerPl-sCnc |
|
|
|
Y |
|
Acecainide; Acetylprocanam; DRUG/TOXICOLOGY; Drugs; Level; NAPA; PA; Pl; Plasma; Plsm; Point in time; Procainamide+NAPA; Procan; Pronestyl; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
1489-4 |
Gastrin^5M post 0.2 U/kg secretin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gastrin [Mass/volume] in Serum or Plasma --5 minutes post 0.2 U/kg secretin |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1489-4 |
|
|
|
|
Observation |
|
|
|
0 |
Gastrin 5M p 0.2 u/kg SCT SerPl-mCnc |
|
|
|
Y |
|
5M p 0.2 u/kg SCT; After; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Total gastrins; Zollinger-Ellison syndrome |
2.34 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14890-8 |
Progesterone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Progesterone [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14890-8 |
|
|
|
|
Both |
|
|
|
0 |
Progest SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Level; P4; Pl; Plasma; Plsm; Point in time; Prog; Proges; Progest; Progestin; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14891-6 |
Propranolol |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Propranolol [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14891-6 |
|
|
|
|
Both |
|
|
|
0 |
Propranolol SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Inderal; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14892-4 |
Propranolol |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Propranolol [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14892-4 |
|
|
|
|
Both |
|
|
|
0 |
Propranolol Ur-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Inderal; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.42 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14893-2 |
Propranolol |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Propranolol [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/24 H |
|
|
|
|
|
|
DRUG/TOX |
|
14893-2 |
|
|
|
|
Both |
|
|
|
0 |
Propranolol 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; DRUG/TOXICOLOGY; Drugs; Inderal; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.42 |
1.0k |
|
|
|
|
|
|
|
nmol/(24.h) |
|
|
|
0 |
14894-0 |
Propylene glycol |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Propylene glycol [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14894-0 |
|
|
|
|
Both |
|
|
|
0 |
Prop glycol SerPl Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; Prop glycol; Ql; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14895-7 |
Protein pattern |
Imp |
Ser/Plas |
Pt |
Nom |
Immunofixation |
|
ACTIVE |
Protein Fractions [Interpretation] in Serum or Plasma by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14895-7 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
Prot Pattern SerPl IFE-Imp |
|
|
|
|
|
Chemistry; IFE; Ifix; Immunofixation electrophoresis; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Pl; Plasma; Plsm; Point in time; PR; Prot; Prot Pattern; Protein fractions; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14896-5 |
Protein pattern |
Imp |
Urine |
Pt |
Nom |
Immunofixation |
|
ACTIVE |
Protein Fractions [Interpretation] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14896-5 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
Prot Pattern Ur IFE-Imp |
|
|
|
|
|
Chemistry; Hematology; Heme; IFE; Ifix; Immunofixation electrophoresis; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Kidney; Nephrology; Nominal; Point in time; PR; Prot; Prot Pattern; Protein fractions; Random; Renal; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14897-3 |
Protein |
MCnc |
Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Protein [Mass/volume] in Plasma |
|
DEL |
DefinitionDescription |
|
|
g/dL |
|
|
|
|
|
|
CHEM |
|
14897-3 |
|
|
|
|
|
|
|
|
0 |
Deprecated Prot Plas-mCnc |
|
|
|
|
|
Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random |
2.4 |
1.0k |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
14898-1 |
Protriptyline |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Protriptyline [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14898-1 |
|
|
|
|
Both |
|
|
|
0 |
Protrip SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Vivactil |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14899-9 |
quiNIDine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
quiNIDine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14899-9 |
|
|
|
|
Both |
|
|
|
0 |
quiNIDine SerPl-sCnc |
|
|
|
Y |
|
Chinidine; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
149-5 |
Cephalexin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Cephalexin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
149-5 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Cephalexin Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefadine; GRACEF; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Keflex; Losporal; Minimum inhibitory concentration; Palitrex; Point in time; Random; Salitex; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1490-2 |
Gastrin^pre 0.2 U/kg secretin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gastrin [Mass/volume] in Serum or Plasma --pre 0.2 U/kg secretin |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1490-2 |
|
|
|
|
Observation |
|
|
|
0 |
Gastrin pre 0.2 u/kg SCT SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre 0.2 u/kg SCT; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Total gastrins; Zollinger-Ellison syndrome |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14900-5 |
raNITIdine |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
raNITIdine [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14900-5 |
|
|
|
|
Both |
|
|
|
0 |
raNITIdine Gast Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Zantac |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14901-3 |
raNITIdine |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
raNITIdine [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14901-3 |
|
|
|
|
Both |
|
|
|
0 |
raNITIdine SerPl Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Zantac |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14902-1 |
raNITIdine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
raNITIdine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14902-1 |
|
|
|
|
Both |
|
|
|
0 |
raNITIdine Ur Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn; Zantac |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14903-9 |
Folate |
Imp |
Bld |
Pt |
Nom |
|
|
ACTIVE |
Folate [Interpretation] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14903-9 |
|
|
|
|
Observation |
|
|
|
0 |
Folate Bld-Imp |
|
|
|
|
|
Blood; Chemistry; Folat; Folic acid; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Pteroylglutamate; Pteroylglutamic acid; Random; Vit M; Vitamin M; WB; Whole blood |
2.26 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14904-7 |
Reagin Ab |
PrThr |
XXX |
Pt |
Ord |
VDRL |
|
ACTIVE |
Reagin Ab [Presence] in Specimen by VDRL |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
14904-7 |
|
VDRL |
|
|
Both |
|
|
|
0 |
VDRL Spec Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Infectious Disease; InfectiousDisease; Microbiology; Microscopic flocculation; Misc; Miscellaneous; Neurosyphilis; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; Syphilis; To be specified in another part of the message; Treponema; Unspecified; Venereal Disease Research Laboratory |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14905-4 |
Retinol |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Retinol [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14905-4 |
|
|
|
|
Both |
|
|
|
0 |
Vit A SerPl-sCnc |
|
|
|
Y |
|
Axerol; Axerophthol; Biosterol; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Vit A; Vit A alcohol; Vit A1; Vit A1 alcohol; Vitamin A; Vitamin A alcohol; Vitamin A1 |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14906-2 |
Rh |
Type |
BldCo |
Pt |
Nom |
|
|
ACTIVE |
Rh [Type] in Cord blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14906-2 |
|
|
|
|
Both |
|
|
|
0 |
Rh BldCo |
|
|
|
|
|
Blood - (umbilical) cord; BLOOD BANK; Cord (umbilical) blood; Cord bld; Cord blood; D phenotyping; D typing; Gyn; Gynecology; Hematology; Heme; Nominal; OB; ObGyn; Obstetrics; Point in time; Random; Rh phenotyping; Rh typing; Typ |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14907-0 |
Rh |
Type |
Bld^BPU |
Pt |
Nom |
|
|
ACTIVE |
Rh [Type] in Blood from Blood product unit |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14907-0 |
|
|
|
|
Observation |
|
|
|
0 |
Rh Bld BPU |
|
|
|
|
|
Blood; BLOOD BANK; Blood product unit; Blood Product Unit (Pack); D phenotyping; D typing; Hematology; Heme; Nominal; Point in time; Random; Rh phenotyping; Rh typing; Typ; WB; Whole blood |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14908-8 |
Rh |
Type |
Bld^Newborn |
Pt |
Nom |
|
|
ACTIVE |
Rh [Type] in Blood from Newborn |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14908-8 |
|
|
|
|
Both |
|
|
|
0 |
Rh Bld NB |
|
|
|
|
|
Blood; BLOOD BANK; D phenotyping; D typing; Hematology; Heme; NB; New born; Nominal; Point in time; Random; Rh phenotyping; Rh typing; Typ; WB; Whole blood |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |